Russia’s competition authority approved of Sistema’s buyout of Veropharm on Monday, and, as a result, shares surged in the Moscow stock exchange for two of nation’s pharmaceutical companies, Veropharm and 36.6. Shares in 36.6 rose 6.7 percent, while shares for Veroharm – Russia’s third largest drug maker – rose 9.7 percent. 36.6 had previously announced it was ready to sell its share in Veropharm, which amounted to 51.8 percent of the company, to pay off debts. Russia’s Federal Anti-Monopoly Service has approved of the merger as long as certain conditions are met, though there is no word yet on what those conditions are.
Featured News
Golden Globes Lawsuit Puts Media Acquisitions and Antitrust Concerns in the Spotlight
Jul 28, 2026 by
CPI
UK Lawsuit Against xAI Highlights Growing Pressure Over AI-Generated Deepfakes
Jul 28, 2026 by
CPI
Google Faces New Wave of Private Antitrust Claims After EU Digital Markets Act Fine
Jul 28, 2026 by
CPI
Shein Faces Fresh FTC Review as US Regulators Tighten Oversight of E-Commerce
Jul 28, 2026 by
CPI
German Cartel Office Fines Maxxis, Two Tire Distributors Over Illegal Pricing Practices
Jul 28, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes